A trans-splicing ribozyme that can specifically reprogram human telomerase reverse transcriptase (hTERT) RNA was previously suggested as a useful tool for tumor-targeted gene therapy. In this study, we applied transcriptional targeting with the RNA replacement approach to target liver cancer cells by combining a liver-selective promoter with an hTERT-mediated cancer-specific ribozyme. To validate effects of this system in vivo, we constructed an adenovirus encoding for the hTERT-targeting trans-splicing ribozyme under the control of a liver-selective phosphoenolpyruvate carboxykinase promoter. We observed that intratumoral injection of this virus produced selective and efficient regression of tumors that had been subcutaneously inoculated with hTERTpositive liver cancer cells in mice. Importantly, the trans-splicing reaction worked equally well in a nude mouse model of hepatocarcinoma-derived peritoneal carcinomatosis, inducing the highly specific expression of a transgene, and moreover, the efficient regression of the hTERT-positive liver tumors with minimal liver toxicity when systemically delivered with the adenovirus. In addition to the observed hTERT-dependent therapeutic gene induction, significant reductions in the levels of hTERT RNA (B75%) were also observed. In conclusion, this study demonstrates that a cancer-specific RNA replacement approach using transsplicing ribozyme with a tissue-selective promoter represents a promising strategy for cancer treatment.
Introduction
The Tetrahymena group I intron ribozyme has been shown to target and cleave a substrate RNA and transsplice an exon tagged at the 3 0 end of the ribozyme onto the cleaved substrate RNA in cells. 1, 2 Therefore, this trans-splicing ribozyme could target and reprogram a specific disease-associated transcript with transgene RNA exerting a therapeutic effect, specifically in cells that express the target RNA, representing an attractive gene therapy tool. [3] [4] [5] Thus, considerable progress has been made in the development of trans-splicing ribozymes for therapeutic applications, such as in the treatment of human genetic or malignant diseases. [6] [7] [8] [9] [10] Previously, we suggested that the trans-splicing ribozyme could be a potent anticancer agent by virtue of its ability of target RNA-specific delivery of anticancer genes to the cancer cells. The rationale is that trans-splicing ribozyme targeting transcripts dominantly expressed in cancer cells would recognize its own substrates, switch them into suicidal gene transcripts and cause eventual cell death. We validated this concept by developing transsplicing ribozymes targeting and replacing human telomerase reverse transcriptase (hTERT) RNA to induce transgene activity specifically in cancer cells that express the RNA, demonstrating that the ribozyme can specifically mark tumor cells expressing hTERT or specifically make tumor cells sensitive to prodrug treatment not only in vitro but in tumor xenografts. [11] [12] [13] This study showed that a trans-splicing ribozyme provides a multifunctional gene therapy tool that both targets and treats the tumor in two ways. A major advantage of this approach is that by invading a tumor-specific pre-mRNA, targeted expression of the therapeutic gene product is guaranteed, with a simultaneous reduction in the expression of the target gene product resulting in an additive, or perhaps a synergistic, anticancer effect.
However, targeting of hTERT mRNA might be limited in terms of tumor selectivity because highly proliferating normal cells, germ cells and stem cells are also telomerase positive. [14] [15] [16] [17] Thus, the hTERT-targeting trans-splicing ribozyme may cause unknown side effects in those cells and tissues, resulting in undesirable side effects. Therefore, adopting tissue-selective promoter to this ribozyme system would enable the therapeutic activity to be selective only to cancer cells and not to normal stem cells. 18 Indeed, we previously showed that cytotoxity of hTERT þ bone marrow-derived cells was hardly induced by liver-specific expression of the ribozyme. 19 These results indicate that translatable and functional transgene products can be selectively generated only in specific hTERT þ tumor tissues, and therefore nonselective gene activation in hTERT þ normal tissues can be suppressed, through tissue-and cancer-restricted expression of the ribozyme.
In this study, we applied the transcriptional targeting with the RNA replacement approach to target liver cancer cells by combining liver-selective promoter with hTERTspecific ribozyme, and evaluated in vivo feasibility of this attempt as a tool for targeted cancer gene therapy. To this end, we constructed an adenoviral vector that encoded for the hTERT-targeting trans-splicing ribozyme under the control of the liver-selective promoter, and then analyzed the efficacy, target RNA specificity and tissue selectivity of this adenovirus in vitro and in vivo.
Materials and methods

Generation of recombinant adenoviral vectors
Expression vectors encoding for hTERT-specific transsplicing ribozymes under the control of cytomegalovirus (CMV) or phosphoenolpyruvate carboxykinase (PEPCK) promoter were constructed as previously described. 11, 19 In brief, the Rib21AS ribozyme targeting U21 on the hTERT RNA was generated to harbor the extended internal guide sequence, which includes as an extension of the P1 helix, an additional 6-nt-long P10 helix, and a 325-nt-long antisense sequence complementary to the downstream region of the targeted hTERT RNA uridine. 11 cDNA as a 3 0 exon encoding for lacZ or herpes simplex virus thymidine kinase (HSVtk) genes was inserted into NruI/XbaI downstream of the modified group I intron expression construct. The resulting ribozyme was then cloned into pcDNA or pPEPCK-LCR (kindly provided by Dr K Oka from the Bayler College of Medicine). The resulting ribozyme cDNA flanked by the promoter and the 3 0 -exon sequence was cloned into the SpeI/BstBI site of the pAdenoVator-CMV5-IRES-GFP shuttle vector (Qbiogene, Irvine, CA). Recombinant adenovirus vectors encoding for the ribozymes were then generated by an in vivo homologous recombination technique in bacteria (BJ5183) as follows. In brief, the shuttle plasmid was linearized with PmeI, and subsequently cotransformed into BJ5183 cells with an E1/E3 deleted adenoviral type5 backbone genome (pAdenoVator DE1/E3; Qbiogene). The recombinant vectors generated through homologous recombination in the BJ5183 cells were isolated and linearized with PacI. The linearized vectors were then transfected into 293 cells, and the produced recombinant adenoviruses were isolated by three rounds of plaque purification. Recombinant viruses were amplified using 293 cells, purified and concentrated with Vivapure AdenoPACK 100 (Sartorius AG, Edgewood, NY). Titers of the recombinant adenovirus were then assessed by TCID50 analysis.
Cell lines and culture conditions
The following cells were purchased from the American Type Culture Collection: SKOV3 (human ovarian cancer cell line), HeLa (human cervical cancer cell line), Hep3B and HepG 2 (human hepatoma cell lines), IMR90 (telomerase negative normal human lung fibroblast) and THLE3 (SV40 large T antigen immortalized but nontumorigenic normal liver cells). The SKOV3 and HeLa cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum (FBS; Jeil Biotech Services Inc., Seoul, Korea), 50 U ml À1 of penicillin G, and 50 mg ml À1 of streptomycin (Sigma, St Louis, MO). The HepG2, Hep3B and IMR90 cells were cultured in Eagle's Minimal Essential Medium with 10% FBS. The THLE3 cells were cultured in bronchial/tracheal epithelial cell growth medium (Cambrex, East Rutherford, NJ) with 10% FBS, 6.5 ng ml À1 of triiodothyromine, 50 mg ml À1 of gentamycin and 50 ng ml À1 of amphotericin-B.
Cell proliferation (MTS) assay
Cell proliferation (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS)) assays were employed using the standard protocols with minor modifications. The cells were seeded at 5 Â 10 3 cells per well (0.1 ml) in 96-well plates and incubated overnight at 37 1C. Triplicate wells were then infected with varying multiplicities of infection (MOI) of adenoviruses. At 1 day post infection, 100 mM of ganciclovir (GCV; Cymevene; Roche, Basel, Switzerland) was added to each plate, and the cells were incubated for an additional 5 days. CellTiter 96Aqueous one solution reagent (20 ml; MTS; Promega, Madison, WI) in 100 ml of Opti-MEM was then added to each well, and incubated for 1-4 h, based on the rate of color change. Cell viability was estimated by determinations of absorbance at 490 nm. Cell survivability after GCV treatment was calculated as the fraction of the absorbance found in cells without GCV treatment, and then represented as the percentage relative to that of the mock-infected cells.
Animals
Male BALB/cAnNCrI nude mice (4-to 5-week old; Orient Bio Inc., Seongnam, Korea) were utilized throughout this study. The animals were maintained under specific pathogen-free conditions, acclimated to laboratory conditions for at least 1 week before use, and maintained in a Korean Food and Drug Administration animal facility in accordance with AAALAC International Animal Care policy (accredited unit-Korea Food and Drug Administration, unit number-000996).
Assessment of in vivo therapeutic efficacy in tumor xenografts
For the subcutaneous tumor model in mice, Hep3B (2 Â 10 7 cells) or HeLa cells (1 Â 10 7 cells) were injected into the flanks of male nude mice. Typically 3 weeks (Hep3B) or 2 weeks (HeLa) after inoculation, tumor nodules achieved a size of 6-9 mm in diameter. The mice were then assigned randomly to two treatment groups (Ad-PEPCK.Ribo-TK, PRT, and Ad-CMV.Ribo-TK, CRT) and one control group (Ad-PEPCK-LacZ, PL). Preestablished tumors were injected with 1 Â 10 9 PFU of viruses. The injections were repeated once, 5 days after the first injection. One day after the initial adenoviral injection, the animals were treated daily with 50 mg kg
À1
GCV for a period of 10 days. Tumor growth was monitored by periodic measurements with calipers every 2-3 days, and the tumor volume was calculated using the following formula: (maximal length) Â (perpendicular width) 2 /2.
Peritoneal carcinomatosis model
For the peritoneal carcinomatosis model of Hep3B liver cancer cells, 2 Â 10 7 Hep3B cells were injected intraperitoneally into male nude mice. In the pilot investigation, the animals evidenced peritoneal carcinomatosis within 21 days, which was readily detectable by gross inspection using a binocular stereomicroscope. In order to analyze specific transgene induction, we injected 1 Â 10 9 PFU of PL or Ad-PEPCK.Ribo-LacZ in phosphate-buffered saline (PBS, total volume, 100 ml) intraperitoneally three times at 2-day intervals after the establishment of carcinomatosis. At 2 days after the last viral injection, the animals were intracardially perfused with 4% paraformaldehyde under deep anesthesia. All abdominal organs and tumors were then removed, rinsed in PBS and the tissues were frozen and cryosectioned into 20 mm-thick slices for immunohistochemical analysis and hematoxylin and eosin (H&E) staining, or lysed for b-galactosidase assays. In order to assess the antitumor affects, the mice to which intraperitoneal tumors had been introduced after 2.5 weeks of intraperitoneal injection of Hep3B were randomized into the following groups (n ¼ 10 mice per each group): (1) PL, (2) PRT and (3) CRT. We then administered intraperitoneal injections with 2.5 Â 10 10 v.p. of each adenovirus three times at 2-day intervals, and GCV (50 mg kg
À1
) was administered for 10 days after the initial viral injection. At 2.5 weeks after virus treatment (total 5 weeks after Hep3B injection), the intraperitoneally established tumor nodules were collected and photographed. The total mass of tumors in each of the mice was then measured. To determine the reduction level of the hTERT RNA affected by the ribozyme in vivo, hTERT cDNA was amplified through real-time PCR from the 2 mg total RNA of the hepatocarcinoma in mice 2 days after the final adenoviral infection of the intraperitoneal carcinomatosis model mice. The sequences of the primers for the hTERT amplification were as follows: 5 0 -CGGAA GAGTGTCTGGAGCAA-3 0 and 5 0 -GGATGAAGCG GAGTCTGGA-3 0 . All reagents with the exception of Taq polymerase (Takara, Otsu, Japan) were obtained for analysis from the SYBR-Green core reagent kit (Molecular Probes, Eugene, OR). The protocol was conducted in accordance with the instructions in the manual for the PCR kit. The conditions for the PCRs were as follows: at 95 1C for 30 s, 55 1C for 40 s and 72 1C for 1 min, for 40 cycles. We used GAPDH to control for the standard curve in the reaction mix. The threshold levels obtained from the hTERT were adjusted to the threshold levels found in the GAPDH reaction in order to correct for minor variations in cDNA loading. For amplification, we used the Rotor-Gene system, a real-time PCR machine (Corbett, San Francisco, CA).
RNA analysis
b-Galactosidase assay and immunohistochemistry At 2 days after the final injection of PL or Ad-PEPCK.Ribo-LacZ into the mice with intraperitoneally established carcinomatosis, hTERT-dependent transgene expression was qualitatively assessed by X-gal staining in accordance with the manufacturer's instructions, using a b-galactosidase staining kit (Invitrogen). After killing, the organs and tumors were removed, sectioned and frozen in a cryoprotective medium (Sakura Finetek, Zoeterwoude, The Netherlands). Frozen sections (8 mm) were fixed with 2% paraformaldehyde in 100 mmol l À1 of PBS (pH 7.4) for 10 min at room temperature. The sections were washed twice in PBS, and stained with X-gal solution at 37 1C, overnight. The sections were then counterstained with H&E and observed under light microscopy. Alternatively, the organs removed from the adenovirally infected mice (wet weight of approximately 100 mg) were extracted with lysis buffer (200 ml: 0.1 M Tris-HCl, 2 mM EDTA and 0.1% Triton X-100, pH 7.8) for 15 min at room temperature. Samples were centrifuged at 13 000 r.p.m. for 10 min at 4 1C. The supernatants (100 ml) were then transferred to 1.5 ml tubes, and 400 ml of o-nitrophenyl-b-D-galactopyranoside (ONPG) solution (120 mM Na 2 HPO 4 , 80 mM NaH 2 PO 4 , 2 mM Mg 2 SO 4 , 100 mM b-mercaptoethanol, 4 mg ml À1 ONPG; Sigma) was added. After 30 min at 37 1C, the reaction was halted by the addition of 500 ml of 1 M Na 2 CO 3 and read on a UV spectrometer (Bio-Rad, Hercules, CA) at a wavelength of 420 nm. For telomerase expression in the tumor nodules obtained from the above adenoviral-treated mice, immunohistochemistry were conducted using the avidin-biotin-peroxidase complex technique with the DAKO EnVision Kit (Dako, Carpinteria, CA) on formalin-fixed and paraffin-embedded specimens that were dewaxed and rehydrated using graded alcohols. Endogenous peroxidase was blocked by the immersion of the sections in 3% aqueous hydrogen peroxide for 10 min. Antigens were retrieved by 10 min of microwave treatment in 10 mmol l À1 of citrate buffer, pH 6.0. Diluted primary antibodies (1:100) against hTERT (Santa Cruz Biotechnology, Santa Cruz, CA) were treated for 1 h at room temperature. The sections were then incubated with the secondary antibody and the avidin-biotin-peroxidase complex. The slides were slightly counterstained with H&E.
Statistical analysis
Statistical analysis was conducted using Statistical Analysis System (SAS) software (SAS Institute, Cary, NC). The between-group differences were assessed through analysis of variance (ANOVA). In the case of highly skewed distribution of measurements and small sample sizes, we employed nonparametric statistical tests (Kruskal-Wallis test for overall comparison and Wilcoxon's rank-sum test for pair-wise comparison). All data were expressed as the means±standard deviation. P-values of o0.05 were considered statistically significant.
Results
Ad-PEPCK.Ribo-TK with GCV treatment specifically and efficiently induces cytotoxicity in hTERT þ liver cancer cells To evaluate the therapeutic effects against hepatocellular carcinoma (HCC) of the liver-selective expression of the hTERT-targeting trans-splicing ribozyme, we constructed an adenoviral vector encoding for the specific ribozyme with the (HSVtk) gene under the control of a PEPCK promoter (Ad-PEPCK.Ribo-TK, PRT; Figure 1a ). In our previous in vitro study, the expression of the specific ribozyme harboring diphtheria toxin A or HSVtk with the PEPCK promoter was shown to be the most effective and specific with regard to the retardation of the growth of hTERT þ liver cancer cells, as compared with other liver-specific promoters. 19 We constructed adenoviruses encoding for the bacterial b-galactosidase (lacZ) gene (Ad-PEPCK-LacZ, PL) and the HSVtk gene (Ad-PEPCK-TK, PT) under the control of the PEPCK promoter only, as a negative control and as a control for the analysis of target RNA specificity of the ribozyme, respectively (Figure 1a ). Moreover, we generated an adenoviral vector encoding for the ribozyme with the HSVtk gene under the control of the strong constitutional CMV immediate early promoter (Ad-CMV.Ribo-TK, CRT) for comparison of tissue selectivity of the ribozyme.
We then determined and compared the cytotoxicity after treatment of varying amounts of the adenoviruses with GCV in a variety of cell lines including hTERT þ liver cancer cells, hTERT þ nonliver cancer cells and hTERT À nontumorigenic cell lines. Noticeably, the PT virus was cytotoxic in liver cells (Hep3B, HepG2 or THLE3 cells) independent of hTERT status, whereas the PRT virus specifically killed hTERT þ liver cancer cells but not hTERT À THLE3 liver cells, indicating target RNA specificity of the ribozyme. Interestingly, the PRT virus was more effective than the PT virus with regard to the cytotoxic induction in hTERT þ liver cancer Hep3B cells (Figure 1b) . Adenoviruses encoding for hTERTtargeting ribozyme induced negligible HSVtk gene activity in the hTERT À IMR90 or THLE3 cells even at the highest concentrations, regardless of the promoter systems employed for the ribozyme expression. However, the CRT virus efficiently induced HSVtk gene activity in a dose-dependent, but not selective, manner, and thus stimulated cytotoxicity with GCV treatment in all types of the hTERT þ cancer cells. In sharp contrast, the PRT virus induced cytotoxicity efficiently and selectively only in hTERT þ liver cancer cells with GCV treatment (Figure 1b) . We conducted the same experiments with a fixed dose of adenovirus and varying GCV concentrations in order to assess the GCV concentration dependency of the adenoviral cytotoxicity (Supplementary Figure S1a) We determined whether the PRT virus-mediated selective killing of liver cancers is due to a specific and high fidelity trans-splicing reaction with hTERT RNA in those cells. CRT infection generated trans-spliced molecules (TSMs) in hTERT þ Hep3B and SKOV3 cells but not in hTERT À IMR90 cells, even though ribozymes (represented as TK RNA) were expressed in the IMR90 cells. In contrast, ribozymes were selectively expressed in liver cancer Hep3B cells by PRT, resulting in the production of TSM only in the cells (Figure 1c) . No TSM was detected in an RNA sample isolated from mock-infected Hep3B cells mixed with CRT-infected IMR90 (mix lane). Thus, we could conclude that TSM in PRT-infected Hep3B cells were generated through the liver-specific trans-splicing reaction with target hTERT RNA. Moreover, even though we detected the presence of ribozyme transcripts in THLE3 cells infected with PRT, CRT or PT virus, no TSM were produced in any of the virus-infected THLE3 cells, suggesting hTERT dependency for the ribozyme activity (Supplementary Figure  S2) . Sequence analyses of the TSM verified that the PRT virus accurately targeted U21 of the hTERT RNA and spliced its 3 0 exon into the target RNA in the cells (Figure 1c) . We detected PRT viral vector DNA in the SKOV3 and IMR90 cells as well as in the Hep3B, thereby indicating that the selective expression of the ribozyme in the Hep3B cells was not attributable to the specific cell tropism of the PRT virus (Supplementary Figure S1b) .
Efficient and selective regression of human HCC xenografts following intratumorally delivered Ad-PEPCK.Ribo-TK plus GCV In an effort to evaluate the efficacy of PEPCK promoterdriven ribozyme expression in vivo, we established HCC xenografts with hTERT þ Hep3B cells subcutaneously in athymic mice and injected PL, PRT or CRT virus directly into the growing tumors. Tumors that were injected with the control virus, PL and treated with GCV grew continuously, up to 2 cm in diameter at the 20th day after virus injection. In sharp contrast, treatment with PRT/GCV or CRT/GCV induced a dramatic regression of the Hep3B tumors to less than 3 mm in diameter (Figure 2a , ANOVA; Po0.0001). Of note, complete tumor regression was observed in three of mice infected with either PRT or CRT. As seen in the in vitro cell cytotoxicity analysis, no statistically significant difference was detected in terms of tumor regression upon treatment with PRT/GCV and with CRT/GCV (ANOVA; P ¼ 0.41). To determine the in vivo tissue selectivity of the PRT virus, we established HeLa-derived human cervix carcinoma in nude mice. At 20 days after the initial viral injection, tumor sizes were significantly reduced (by 40%) as the result of CRT/GCV treatment, as compared to the control treatment (ANOVA; Po0.05). However, no significant change in the sizes of cervical tumors was observed in the PRT/GCV treatment group (ANOVA; P ¼ 0.7857; Figure 2b ). These results showed that the HSVtk induction of PRT rendered tumor growth inhibition only in hepatocarcinoma xenografts, with almost equal efficacy to that of CRT.
Ad-PEPCK.Ribo-LacZ specifically targets hTERT þ HCC in a murine model of intraperitoneal carcinomatosis and efficiently reduces hTERT mRNA level in the tumor In an attempt to evaluate the specificity and efficacy of the liver-specific hTERT-targeting ribozyme under more clinically relevant conditions, we established a human hepatocarcinoma-derived peritoneal carcinomatosis model by the intraperitoneal injection of Hep3B cells into nude mice. Multiple Hep3B tumor nodules were formed in the mice abdomen 3 weeks after intraperitoneal tumor inoculation. We compared ribozyme activity of Ad-PEPCK.Ribo-LacZ (PRL) with PL. In the PL-injected control mice, we observed lacZ expression not only on the surface of the normal liver but also in the developed tumor nodules of mice. In contrast, PRT selectively induced lacZ expression in the tumor nodules, but not on the liver surface (Figure 3a) . Tumor-specific lacZ expression by PRL was also determined by b-galactosidase activity analyses in the various tissue extracts of mice with peritoneal carcinomatosis (Figure 3b) . No significant differences were detected in the level of PRL-induced b-galactosidase in the different tumor nodules. These results showed that Ad-PEPCK.Ribo-LacZ specifically and effectively induced transgene expression in vivo.
In order to determine whether and to what degree the adenoviral vector encoding for the specific ribozyme could reduce intracellular levels of target RNA, we compared the amount of hTERT mRNA in the tumor nodules of PRL-injected mice with those seen in the tumors of PL-infected mice, using real-time PCR. The steady-state level of hTERT RNA was reduced considerably (up to 75%) by PRL (Figure 3c) . Consistent with the RNA reduction, the PRL-treated mice evidenced a significant reduction in hTERT protein expression in the tumor nodules (Figure 3d ). Rapid amplification of cloned ends reverse transcriptase (RT)-PCR analysis revealed that all of the trans-splicing products generated in the HCC of the PRL-injected mice were resulted from reactions with only the targeted hTERT RNA, implying the in vivo target specificity of the trans-splicing ribozyme (data not shown). Collectively, these results showed that the PEPCK promoter-driven trans-splicing ribozyme specifically targeted the hTERT RNA and efficiently reduced the RNA levels of the target in vivo.
Efficient regression of hepatocarcinoma in peritoneal carcinomatosis mice following systemically delivered Ad-PEPCK.Ribo-TK plus GCV We determined whether the hepatocarcinomas established in the peritoneal carcinomatosis murine model were regressed after the systemic delivery of PRT. For the analysis of tumor specificity by PRT in terms of tumor regression, first we observed and compared liver toxicity in nontumor-bearing mice systemically infected by Ad-PEPCK-TK (PT) or PRT virus (Figure 4) . We injected 2.5 Â 10 10 v.p. of PL, PT or PRT virus into male BALB/c nude mice tail veins followed by GCV treatment for 10 days. We killed five mice from each group at days 2, 7 and 14 after GCV treatment and evaluated liver morphology and liver enzyme levels (serum aspartate aminotransferase, AST, and alanine aminotransferase, ALT).
The livers treated with PRT showed no remarkable changes, similar to livers treated with PL, till 14 days. This seems to be because of no targetable hTERT RNA in the normal mouse liver, inducing no HSVtk activation by PRT. On contrary, PT-treated liver showed occasional hepatocyte degeneration from 2nd day, and remarkably frequent apoptosis, spotty necrosis in addition to hepatocyte degeneration at 7th day, continuing till 14th day, which is mainly due to nonspecific HSVtk expression in the normal liver (Figure 4a ). In addition, no differences were shown in liver enzyme levels between PL-and PRTinfected mice. By contrast, significant elevation of serum ALT/AST levels was observed in PT group at days 7 and 14 when compared to PL or PRT group (Figure 4b) . Thus, systemic infection with PRT combined with GCV inoculation was well tolerated with minimal liver toxicity at the viral dose of 2.5 Â 10 10 v.p. The mice with peritoneal carcinomatosis were established and killed before viral injection, and their abdominal cavities were investigated in order to determine the degree to which tumor nodules had been generated (Figure 5a ). The injection of Hep3B cells into mice led to reproducible (490%) and diffuse intraperitoneal tumor nodules located on the small bowel mesentery, the hepatic hilum and the surface of the diaphragm. The established peritoneal carcinomatosis mice were injected with 2.5 Â 10 10 v.p. of PL, PRT or CRT, treated with GCV, and killed 1 week after final GCV inoculation (5 weeks after Hep3B injection into the mice), and their tumors were examined for growth ( Figure 5a ). As compared with the control mice with PL/GCV treatment, the numbers of tumor nodules and their volume were highly regressed in either group of mice with PRT/GCV or CRT/GCV treatment (Figures 5a  and b) . Interestingly, the livers of mice treated with PRT or CRT either evidenced no remaining tumor nodules or very small nodules, different from the large tumor nodules that had grown in the livers of the PL-treated control mice (Figure 5b) . The average tumor masses were 0.53 ± 0.41 g for the 2.5 week pretreatment group, 8.26 ± 2.97 g for the PL group, 3.52±1.99 g for the PRT group and 2.36 ± 1.39 g for the CRT group (Figure 5c ). Significant reductions in tumor generation were noted in the group of mice treated with the adenovirus encoding for the hTERT-targeting ribozyme, as compared with the mice group treated with the control adenovirus (Po0.001). PRT proved equally as potent as CRT in terms of its ability to suppress the tumor growth in the peritoneal mice model (P ¼ 0.1496).
We determined whether the adenoviral-mediated suicide gene induction in HCC of peritoneal carcinomatosis mice model was ascribable to a specific and high-fidelity trans-splicing reaction with the hTERT RNA of the HCC. Contrary to what was observed with the ribozyme, which was expressed in the normal liver as well as in the individual tumor nodules of mice injected with PRT, TSM was generated only in the tumor nodules, which suggests that the systemic delivery of the adenovirus specifically targeted tumors in vivo through the transsplicing reaction with hTERT only (Figure 5d ). TSM was also produced selectively in the established HCC of CRTinfected mice (data not shown). A little difference in the quantity of TSM was observed between individual tumors as the result of PRT treatment. PRT correctly targeted and spliced the HSVtk RNA onto the targeted hTERT site in the established tumor nodules (Figure 5e ). We still observed TSM generation and the correct hTERT mRNA target sequence in the residual tumor nodules of mice treated with the ribozyme-encoding adenovirus and GCV (tumors 1 week after final GCV inoculation), thereby indicating that the tumor residuals remained probably due to the silencing of HSVtk activity as the result of the cessation of GCV, but not as the result of the inactivation of the ribozyme nor as a consequence of the occurrence of escape mutation in the target RNA in the tumors (Supplementary Figure S3) . Taken together, the in vivo results suggested that PRT exerts significant anti-HCC effects through specific transsplicing reactions in the mouse model of peritoneal carcinomatosis.
Discussion
In this study, we have described in vivo target RNA specificity, tissue selectivity and efficacy of Tetrahymena group I-based hTERT-derived cancer-specific transsplicing ribozyme driven by liver-selective promoter. We selected hTERT RNA for cancer-specific targeting because telomerase activity is elevated in 85-90% of human cancers and its activity is regulated mainly by hTERT expression. 20, 21 Moreover, telomerase reactivation exerts an important effect on the continuous growth of advanced malignancies. 22 For the liver-selective targeting of the ribozyme, we expressed the hTERT-specific ribozyme under the control of the PEPCK promoter. The PEPCK gene is expressed most abundantly in the liver, and the PEPCK promoter significantly activates transgene transcription in liver cancer cells. 23 Previously, we also demonstrated that the transiently intracellular expression of the hTERT-specific ribozyme using the PEPCK promoter induced anticancer activity in liver cancers with the highest degree of efficacy and specificity, in comparison with other promoters. 19 For the in vivo ribozyme delivery, adenoviral vectors were used in this study because they have been shown to efficiently transduce hepatocytes 24 and have been employed in both in vitro and in vivo strategies against a variety of cancers, including HCC. 25 We demonstrated that systemic infection with Ad-PEPCK.Ribo-LacZ specifically and efficiently induced b-galactosidase activity in the HCC, but not in normal liver, of intraperitoneal carcinomatosis model mice. Moreover, in contrast with hTERT-independent cytotoxicity by Ad-PEPCK-TK in normal as well as liver cancer cells, treatment with PRT induced suicide gene activity, and hence specifically cell regression in hTERT þ HCC, but not in normal liver cell. PRT selectively and efficiently regressed hTERT þ HCC growth in the presence of prodrug GCV also in subcutaneously established hepatocarcinomas. Furthermore, the systemic introduction of PRT into the intraperitoneal carcinomatosis mice also efficiently retarded the growth of the HCC in the mice model, with negligible hepatotoxicity in normal mouse liver. The liver cancer-specific transgene induction with the adenovirus occurred primarily as the result of specific RNA replacement occurring through the ribozyme-mediated intracellular trans-splicing reaction with the target hTERT RNA. Simultaneously with the induction of the hTERT-dependent therapeutic gene, the systemic introduction of the ribozyme resulted in a significant reduction in the level of target hTERT mRNA in the peritoneally established HCC. Therefore, the tissueselective expression of the trans-splicing ribozyme may constitute a highly promising anticancer approach by virtue of a combination of the following three capabilities: (1) tumor-restricted stimulation of therapeutic gene activity, (2) transcriptional targeting to the selective cancer-originated tissue and (3) efficiently targeted telomerase inhibition.
Specificity and efficacy should be considered to be important criteria with regard to the successful application of gene therapeutic protocols in clinical cancer treatment. The liver-selective expression of the cancer RNA-specific trans-splicing ribozyme, a key feature of the protocol proposed herein, improved the tissue-selective targeting of the ribozyme in vivo as well as in vitro. The specific activation of transgene activity was noted only in hTERT þ HCC even by systemic delivery of the ribozyme, but this was not observed in normal tissues in the intraperitoneal carcinomatosis mice model. Of note, no misspliced products were found in HCC of the ribozymedelivered mice, thereby precluding the possibility of transgene induction by off-target effect. Specificity of the ribozyme in vivo was further confirmed by the observation of no toxicity in normal hTERT À liver tissue of mouse intravenously infected with the HSVtkharboring ribozyme. In contrast, HSVtk expression under the PEPCK promoter only (Ad-PEPCK-TK) induced nonspecific and hTERT-independent cytotoxicity in cultures and nonspecific toxicity in normal mouse liver in vivo. These results indicate that translatable and functional transgene products can be specifically and selectively generated only in specific hTERT þ tumor tissues, and therefore nonspecific gene activation in hTERT þ normal tissues can be suppressed, through tissue and/or cancer-restricted expression of the ribozyme. Moreover, cell tropism of the adenovirus will limit potential transgene activity in hTERT þ stem cells. 24 Ribozyme-mediated transgene induction might be further minimized in stem cells as the consequence of intermittent proliferation and minimal telomerase activity occurring during quiescence of the cells. 14 Alternatively, local delivery through hepatic artery 26 or direct intrahepatic injection 27 instead of systemic administration would provide added safety in humans. However, more detailed toxicological studies will be required before the application of the ribozyme in clinical settings. Possibility of undesirable side effects on regenerating liver tissues could not be ruled out. This fact may be a major drawback of this system for using therapeutics for HCC, because most HCC accompanies liver cirrhosis with regenerating lesions. 17 Further investigations for searching alternative promoters or ribozyme target genes are required. Of note, genome studies are being conducted in efforts to elucidate the molecular alterations occurring in HCC, 28 which will provide more specific targets for the trans-splicing ribozyme for the purposes of application to HCC therapy.
In order to evaluate in vivo toxicity and/or immune response caused by the ribozyme delivery, immunecompetent mouse model with orthotopic or syngeneic cancer will be more appropriate than immunodeficient xenotransplant mice model utilized in this study. To this effect, we should design a mouse TERT (mTERT)-targeted ribozyme. In marked contrast with undetectable expression of hTERT in most normal human somatic cells, however, robust levels of mTERT are expressed in a wider range of normal somatic tissues and cells in Mus musculus, mice used in research laboratories. 29 Therefore, studies with mTERT-targeting ribozyme cannot fully reflect the feasibility of the ribozyme for human cancer treatment. Mouse models closer to humans in terms of telomerase regulation 30 will be useful for the assessment of in vivo toxicity of the TERT-targeting ribozyme.
The use of an adenoviral vector with a tissue-or tumor-selective promoter has been previously proposed as a method for the expression of a therapeutic gene for targeted cancer gene therapy. 31 Noticeably, our approach is to deliver a therapeutic gene activity by targeting a cancer-specific transcript and simultaneously to inhibit the target gene function rather than simply expressing the therapeutic gene product. Indeed, PEPCK-driven expression of the HSVtk-harboring hTERT-specific ribozyme was more potent cytotoxic at least in Hep3B cells than simple expression of the suicide gene under the PEPCK promoter. However, the low expression levels resulting from weak promoter activity limit the methods that can truly be employed as effective cancer therapies. 32 In this study, however, the selective induction of the HSVtk gene with the adenovirus encoding for the ribozyme under the control of the PEPCK promoter (PRT) caused the regression of hTERT þ liver cancers with efficiency comparable to that associated with the adenovirus harboring the strong CMV promoter-derived ribozyme (CRT) with GCV treatment. Human liver tumors implanted subcutaneously into nude mice were regressed efficiently when inoculated with PRT and GCV, which was also associated with an efficacy comparable to that of CRT. Importantly, both the number and weight of HCC tumor nodules established intraperitoneally in nude mice were significantly reduced when systemically treated with PRT and GCV, with almost the same efficiency as that of CRT. These results strongly suggest that the level of HSVtk RNA spliced by the PEPCK-driven ribozyme (B75% of hTERT RNA level in vivo) may prove sufficient to induce tumor regression in vivo as well as in vitro with prodrug treatment, and PRT can efficiently circumvent HCC growth without compromising its liver cancer specificity.
Human cancer cells were shown to have a rapid and defined growth inhibitory response in vitro to telomerase depletion, even without telomere shortening. [33] [34] [35] In this study, systemic delivery of the ribozyme-encoding adenovirus efficiently attenuated the levels of both hTERT RNA and protein in the HCC nodules of peritoneal carcinomatosis mice. However, no regression of HCC nodules was observed in vivo with Ad-PEPCK. Ribo-LacZ even if the virus caused efficient reduction of telomerase. This finding suggests that such hTERT inhibition levels by the ribozyme may not be sufficient for the suppression of tumor cell growth in vivo. Alternatively or additively, cell subpopulations, which are capable of evading a short-term growth inhibition response, would grow out. A long lag phase will be required for bulk telomere shortening before any detrimental effects on those cells, which could limit the anticancer approach with only repression of hTERT level. 36 Therefore, the hTERT-targeting trans-splicing ribozyme will have the advantage of cumulative effects of hTERT level reduction and targeted therapeutic gene induction, which can overcome the lag phase.
In conclusion, this study demonstrates that a cancerspecific RNA replacement approach using trans-splicing ribozyme with tissue-selective promoter represents a promising strategy for cancer gene therapy. Recently, we developed trans-splicing ribozymes that targeted a variety of targets including carcinoembryonic antigen, 37 a-fetoprotein, 38 or mouse cytoskeleton-associated protein 2 transcript, 39 and demonstrated that the ribozymes both efficiently and specifically retarded the survival of cancer cells expressing the corresponding target RNA in vitro. Further in vivo evidence will indicate the general feasibility of the trans-splicing ribozyme for purposes of cancer gene therapy.
